Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Renaud, S.
Right arrow Articles by Steck, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Renaud, S.
Right arrow Articles by Steck, A. J.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Peripheral neuropathy
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2006;66:742-744
© 2006 American Academy of Neurology
Brief Communications

High-dose rituximab and anti-MAG–associated polyneuropathy

S. Renaud, MD, P. Fuhr, MD, M. Gregor, MD, K. Schweikert, MD, D. Lorenz, MD, C. Daniels, MD, G. Deuschl, MD, A. Gratwohl, MD and A. J. Steck, MD

From the Departments of Neurology (S.R., P.F., K.S., A.J.S.) and Haematology (M.G., A.G.), University Hospital, Basel, Switzerland, and Department of Neurology (D.L., C.D., G.D.), Christian-Albrechts-Universität, Kiel, Germany.

Address correspondence and reprint requests to Dr. Susanne Renaud, Department of Neurology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland; e-mail: srenaud{at}uhbs.ch

Rituximab has been administered successfully in patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750 mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.

Disclosure: Dr. Renaud has nothing to disclose. Dr. Fuhr served on a scientific advisory board of Novartis and received financial support for research activities from Schering Inc. for neurophysiological measurements in multiple sclerosis. Dr. Gregor served on an advisory board of Jansen-Cilag, Switzerland. Dr. Gratwohl served on scientific advisory boards of Novartis, Roche, and Pfizer and received financial support for research activities from Novartis, AMGEN, and Pfizer. Drs. Schweikert, Lorenz, Daniels, and Deuschl have nothing to disclose. Dr. Steck served on the advisory board of Pfizer and received financial support for research activities from Bühlmann Laboratories, Switzerland. For the present study, rituximab was provided free of charge from Roche, Switzerland.

Received May 23, 2005. Accepted in final form November 20, 2005.




This article has been cited by other articles:


Home page
 Therapeutic Advances in Neurological DisordersHome page
H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung
Review: Pathogenesis and treatment of immune-mediated neuropathies
Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
P. H. Lalive, A. Truffert, M. R. Magistris, T. Landis, and A. Dosso
Peripheral Autoimmune Neuropathy Assessed Using Corneal In Vivo Confocal Microscopy
Arch Neurol, March 1, 2009; 66(3): 403 - 405.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. Benedetti, C. Briani, D. Franciotta, M. Carpo, L. Padua, G. Zara, R. Zambello, M. P. Sormani, G. L. Mancardi, E. Nobile-Orazio, et al.
LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY
Neurology, November 18, 2008; 71(21): 1742 - 1744.
[Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Dalakas
Invited Article: Inhibition of B cell functions: Implications for neurology
Neurology, June 3, 2008; 70(23): 2252 - 2260.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J.M.F. Niermeijer, M. Eurelings, M. W. van der Linden, H. M. Lokhorst, H. Franssen, K. Fischer, L. L. Teunissen, L. H. van den Berg, F. Schobben, J. H.J. Wokke, et al.
Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy
Neurology, July 3, 2007; 69(1): 50 - 59.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Vijay and M. A. Gertz
Waldenstrom macroglobulinemia
Blood, June 15, 2007; 109(12): 5096 - 5103.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.